| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_chr6_0688100 | Intergenic-Intergenic | chr6:87959135-87959865 | chr6:87249417-87250147 | 731 nt | 0.4077 |
| hsa_ZNF292_0010400 | Exon-Exon | chr6:87964368-87971508 | chr6:87254650-87261790 | 250 nt | 0.3120 |
| hsa_ZNF292_0010500 | Exon-Exon | chr6:87966601-87968523 | chr6:87256883-87258805 | 1923 nt | 0.4046 |
| hsa_ZNF292_0010600 | Exon-Exon | chr6:87966763-87966974 | chr6:87257045-87257256 | 212 nt | 0.4151 |
| hsa_ZNF292_0010700 | Exon-Exon | chr6:87967891-87969872 | chr6:87258173-87260154 | 80 nt | 0.3625 |
| hsa_chr6_0688200 | Intergenic-Intergenic | chr6:87968383-87968676 | chr6:87258665-87258958 | 294 nt | 0.3061 |
| hsa_chr6_0688300 | Intergenic-Intergenic | chr6:87968810-87968964 | chr6:87259092-87259246 | 155 nt | 0.3677 |
| hsa_chr6_0688400 | Intergenic-Intergenic | chr6:87971754-87972431 | chr6:87262036-87262713 | 678 nt | 0.2994 |
| hsa_chr6_0688500 | Intergenic-Intergenic | chr6:87972987-87974220 | chr6:87263269-87264502 | 1234 nt | 0.2950 |
A study in mice demonstrated that the circZNF292 is hypoxia-induced and regulates Wnt/β-catenin pathway components to promote glioma proliferation and tube formation [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In rat models of myocardial ischemia, the circZNF292 was highly expressed following oxygen glucose deprivation treatment, and its overexpression was shown to release OGD-induced damage [Tian et al. DOI:10.3390/molecules26041155]. A study in human hepatoma cells demonstrated that the circZNF292 promotes hypoxic cell proliferation, vasculogenic mimicry, and radioresistance via the Wnt/β-catenin pathway, and induces tube formation and spheroid sprouting in endothelial cells [Huang et al. DOI: 10.3390/cells11091381]. Research in human glioma cells further showed that the circZNF292 is hypoxia-induced and regulates Wnt/β-catenin pathway components to promote proliferation and tube formation [Mehta et al. DOI: 10.1016/j.pneurobio.2020.101746].